The Biological and Clinical Significance of Androgen Receptor Variants
Abstract
We achieved all of aims proposed for this project. Aim 1 was to evaluate AR-V7 as a prognostic marker in high-grade prostate cancer (PCa). We found that AR-V7 levels did not predict biochemical recurrence (BCR). Aim 2 was to determine whether AR-V7 levels in lowgrade PCa were prognostic, or predicted concurrent presence of high-grade PCa. We found that neither was the case. However, we did find that the ratio of AR-V1:AR-V7 was higher in low- grade PCa without concurrent high-grade PCa. Since AR-Vl reportedly blocks constitutive androgen signaling of AR-V7, this suggests that activity of AR-V7 in lowgrade PCa might be associated with development of high-grade Pea. Aim 3 was to evaluate the role of AR-V7 in mediating primary castration-resistant PCa (CRPC) in a tumorgraft model. We successfully established tumorgrafts from primary PCa and observed the development of CRPC and androgen- independent gene expression; however, we were unable to correlate AR-V7 levels with development of CRPC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2014
- Accession Number
- ADA609269
Entities
People
- Donna M. Peehl
Organizations
- Stanford University